Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5

Cited by (623)

Items 101–200 of 623

1. PRMT5-mediated arginine methylation of TDP1 for the repair of topoisomerase I covalent complexes
   Ishita Rehman, Suparna Mercy Basu, Subhendu Das, Sangheeta Bhattacharjee, Arijit Ghosh, Yves G. Pommier, Benu Brata Das · 2018 · Nucleic Acids Research
2. Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy
   Emily M. Smith, Wei Zhou, Polina Shindiapina, Saı̈d Sif, Chenglong Li, Robert A. Baiocchi · 2018 · Expert Opinion on Therapeutic Targets
3. Functional Genomics for Cancer Drug Target Discovery
   Benjamin Haley, Filip Roudnicky · 2020 · Cancer Cell
4. Metabolic heterogeneity and adaptability in brain tumors
   Christian E. Badr, Daniel J. Silver, Florian A. Siebzehnrübl, Loic P. Deleyrolle · 2020 · Cellular and Molecular Life Sciences
5. A chemical biology screen identifies a vulnerability of neuroendocrine cancer cells to SQLE inhibition
   Christopher E. Mahoney, David A. Pirman, Victor Chubukov, Taryn Sleger, Sebastian Hayes, Zi Peng Fan, Eric L. Allen, Ying Chen, Lingling Huang, Meina Liu et al. · 2019 · Nature Communications
6. Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors
   Hong Lin, Min Wang, Yang W. Zhang, Shuilong Tong, Raul Leal, Rupa S. Shetty, Kris Vaddi, Juan I. Luengo · 2019 · ACS Medicinal Chemistry Letters
7. Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy
   Hayley C. Affronti, Aryn M. Rowsam, Anthony J. Pellerite, Spencer R. Rosario, Mark D. Long, Justine J. Jacobi, Anna Bianchi, Christoph S. Boerlin, Bryan M. Gillard, Ellen Karasik et al. · 2020 · Nature Communications
8. Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance
   Donjeta Gjuka, Elio Adib, Kendra Garrison, Jianfeng Chen, Yuxue Zhang, Wenjiao Li, Daniel R. Boutz, Candice Lamb, Yuri Tanno, Amin H. Nassar et al. · 2023 · Cancer Cell
9. Determinants of nutrient limitation in cancer
   Mark R. Sullivan, Matthew G. Vander Heiden · 2019 · Critical Reviews in Biochemistry and Molecular Biology
10. Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells
    Claudia Dominici, Nicolas Sgarioto, Zhenbao Yu, Laura Sesma-Sanz, Jean‐Yves Masson, Stéphane Richard, Noël J.‐M. Raynal · 2021 · Clinical Epigenetics
11. Transcriptome-scale RNA-targeting CRISPR screens reveal essential lncRNAs in human cells
    Wen-Wei Liang, Simon Müller, Sydney K. Hart, H. Wessels, A. Méndez-Mancilla, Akash Sookdeo, Olivia Choi, Christina M. Caragine, Alba Corman, Lu Lu et al. · 2024 · Cell · Retracted
12. Discovery of a First-in-Class Inhibitor of the PRMT5–Substrate Adaptor Interaction
    David C. McKinney, Brian J. McMillan, Matthew J. Ranaghan, Jamie A. Moroco, Merissa Brousseau, Zachary Mullin-Bernstein, Meghan O’Keefe, Patrick R. McCarren, Michael F. Mesleh, Kathleen M. Mulvaney et al. · 2021 · Journal of Medicinal Chemistry
13. Canonical Wnt is inhibited by targeting one-carbon metabolism through methotrexate or methionine deprivation
    Lauren Veronica Albrecht, Maggie H. Bui, Edward M. De Robertis · 2019 · Proceedings of the National Academy of Sciences
14. Suppressive effects of tumor cell-derived 5′-deoxy-5′-methylthioadenosine on human T cells
    Frederik C. Henrich, Katrin Singer, Kerstin Poller, Luise Bernhardt, Carolin Dorothea Strobl, Katharina Limm, Axel P. Ritter, Eva Gottfried, Simon Völkl, Bénédikt Jacobs et al. · 2016 · OncoImmunology
15. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine
    Yasaman Barekatain, Jeffrey J. Ackroyd, Victoria C. Yan, Sunada Khadka, Lin Wang, Ko‐Chien Chen, Anton H. Poral, Theresa Tammy Tran, Dimitra K. Georgiou, Kenisha Arthur et al. · 2021 · Nature Communications
16. Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy
    Marta Redondo-Muñoz, Francisco Javier Rodríguez‐Baena, Paula Aldaz, Adrià Caballé, Verónica Moncho-Amor, Maddalen Otaegi-Ugartemendia, Estefanía Carrasco‐García, Ana Olías-Arjona, Irene Lasheras-Otero, Eva Santamaría et al. · 2023 · Nature Metabolism
17. Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target
    Johan Vande Voorde, Rory T. Steven, Arafath Kaja Najumudeen, Catriona A. Ford, Alex Dexter, Ariadna González-Fernández, Chelsea J. Nikula, Yuchen Xiang, Lauren Ford, Stefania Maneta Stavrakaki et al. · 2023 · Nature Metabolism
18. The Bidirectional Relationship Between Cancer Epigenetics and Metabolism
    Luke Izzo, Hayley C. Affronti, Kathryn E. Wellen · 2020 · Annual Review of Cancer Biology
19. MTAP Deficiency–Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer
    Qiangsheng Hu, Yi Qin, Shunrong Ji, Xiuhui Shi, Weixing Dai, Guixiong Fan, Shuo Li, Wenyan Xu, Wensheng Liu, Mengqi Liu et al. · 2021 · Cancer Research
20. Arginine methyltransferases in normal and malignant hematopoiesis
    Sarah Merin Greenblatt, Fan Liu, Stephen D. Nimer · 2016 · Experimental Hematology
21. Metabolic Regulation of Methionine Restriction in Diabetes
    Jie Yin, Wenkai Ren, Shuai Chen, Yuying Li, Hui Ling Han, Jing Gao, Gang Liu, Xin Wu, Yuying Li, Sung Woo Kim et al. · 2018 · Molecular Nutrition & Food Research
22. Polyamine pathway activity promotes cysteine essentiality in cancer cells
    Tong Zhang, Christin Bauer, Alice C. Newman, Alejandro Huerta Uribe, Dimitris Athineos, Karen Blyth, Oliver D.K. Maddocks · 2020 · Nature Metabolism
23. MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation
    Landon John Hansen, Ran Sun, Rui Ryan Yang, Simranjit X. Singh, Lee H. Chen, Christopher J. Pirozzi, Casey J. Moure, Carlee Hemphill, Austin B. Carpenter, Patrick N Healy et al. · 2019 · Cancer Research
24. PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer
    Zhe Wang, Jing Kong, Ying Wu, Juliang Zhang, Ting Wang, Nanlin Li, Jing Fan, Hui Wang, Jian Zhang, Rui Ling · 2017 · Breast Cancer Research and Treatment
25. MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial
    Mrinal M. Gounder, Melissa Lynne Johnson, Rebecca Suk Heist, Geoffrey Ira Shapiro, Sophie C. Postel-Vinay, Frederick Hugh Wilson, Elena Garralda, Gerburg M. Wulf, Caroline Almon, Salah Nabhan et al. · 2025 · Nature Communications
26. Metabolic interactions with cancer epigenetics
    Xia Gao, Michael A. Reid, Mei Kong, Jason W. Locasale · 2016 · Molecular Aspects of Medicine
27. Methyltransferase Inhibitors: Competing with, or Exploiting the Bound Cofactor
    Renato Ferreira de Freitas, Danton Ivanochko, Matthieu Schapira · 2019 · Molecules
28. CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort
    Stephanie Theresa Jünger, Felipe Da Matta Andreiuolo, Martin Mynarek, Inken Wohlers, Sven Rahmann, Ludger Klein‐Hitpaß, Evelyn Dörner, Anja zur Mühlen, Natalia Vélez Char, Katja von Hoff et al. · 2020 · Acta Neuropathologica
29. LKB1 regulates PRMT5 activity in breast cancer
    Hanine Lattouf, Loay Mohamed Hassan Kassem, Julien Jacquemetton, Ali Choucair, Coralie Poulard, Olivier Trédan, Laura Corbo, Mona Diab‐Assaf, Nader Hussein, Isabelle Treilleux et al. · 2018 · International Journal of Cancer
30. Dual regulation of Arabidopsis AGO2 by arginine methylation
    Po Hu, Hongwei Zhao, Pei Zhu, Yongsheng Xiao, Weili Miao, Yinsheng Wang, Hailing Jin · 2019 · Nature Communications
31. A PRMT5-RNF168-SMURF2 Axis Controls H2AX Proteostasis
    Changzheng Du, Landon John Hansen, Simranjit X. Singh, Feiyifan Wang, Ran Sun, Casey J. Moure, Kristen Roso, Paula K. Greer, Hai Yan, Yiping He · 2019 · Cell Reports
32. A planetary health perspective on synthetic methionine
    Cajetan Neubauer, Hannah L. Landecker · 2021 · The Lancet Planetary Health
33. Emerging Opportunities for Target Discovery in Rare Cancers
    Tanaz Sharifnia, Andrew Lee Hong, Corrie Painter, Jesse S. Boehm · 2017 · Cell chemical biology
34. All is not lost: learning from 9p21 loss in cancer
    Pavlina Spiliopoulou, S.Y. Cindy Yang, Jeff P. Bruce, Ben X. Wang, Hal K. Berman, Trevor J. Pugh, Lillian L. Siu · 2022 · Trends in Immunology
35. The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior
    Florian Weinberg, Nadine Reischmann, Lisa Fauth, Sanaz Taromi, Justin Mastroianni, M. Köhler, Sebastian Halbach, Andrea C. Becker, Niantao Deng, Tatjana Schmitz et al. · 2017 · EBioMedicine
36. Skin Pigmentation Genetics for the Clinic
    Stephen A. Ainger, Kasturee Jagirdar, Katie Lee, H. Peter Soyer, Richard A. Sturm · 2017 · Dermatology
37. Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors
    Hong Lin, Juan I. Luengo · 2019 · Bioorganic & Medicinal Chemistry Letters
38. Protein arginine methyltransferase 5: a potential cancer therapeutic target
    Yuanyang Yuan, Hong Nie · 2021 · Cellular Oncology
39. CDKN2A inhibits formation of homotypic cell-in-cell structures
    Liang, Jianqing, Fan, Jie, Wang, Manna, Niu, Zubiao, Zhang, Zhengrong, Yuan, Long, Tai, Yanhong, Chen, Zhaolie, Song, Santai, Wang, Xiaoning et al. · 2018 · Oncogenesis
40. Medicinal chemistry strategies targeting PRMT5 for cancer therapy
    Siyu Fu, Qinwen Zheng, Dan Zhang, Congcong Lin, Liang Ouyang, Jifa Zhang, Lei Chen · 2022 · European Journal of Medicinal Chemistry
41. Chemical Inhibition of Protein Methyltransferases
    Matthieu Schapira · 2016 · Cell chemical biology
42. Drug Discovery and Chemical Biology of Cancer Epigenetics
    Scott A. Ribich, Darren M. Harvey, Robert A. Copeland · 2017 · Cell chemical biology
43. PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
    Chang-Ching A. Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Ming Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew S. Lemoff, Yisheng V. Fang, He Zhang, Yanfeng Zhang et al. · 2024 · Nature Communications
44. Cic Loss Promotes Gliomagenesis via Aberrant Neural Stem Cell Proliferation and Differentiation
    Rui Ryan Yang, Lee H. Chen, Landon John Hansen, Austin B. Carpenter, Casey J. Moure, Heng Liu, Christopher J. Pirozzi, Bill H. Diplas, Matthew S. Waitkus, Paula K. Greer et al. · 2017 · Cancer Research
45. Metabolic Rewiring and Redox Alterations in Malignant Pleural Mesothelioma
    Urso, Loredana, Cavallari, Ilaria, Sharova, Evgeniya, Ciccarese, Francesco, Pasello, Giulia, Ciminale, Vincenzo · 2020 · British Journal of Cancer
46. Systematic profiling of conditional degron tag technologies for target validation studies
    Daniel P. Bondeson, Zachary Mullin-Bernstein, Sydney Oliver, Thomas A. Skipper, Thomas C. Atack, Nolan R. Bick, Meilani Ching, Andrew A. Guirguis, Jason J. Kwon, Carly R. Langan et al. · 2022 · Nature Communications
47. Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma
    Hideki Makinoshima, Shigeki Umemura, Ayako Suzuki, Hiroki Nakanishi, Ami Maruyama, Hibiki Udagawa, Sachiyo Mimaki, Shingo Matsumoto, Seiji Niho, Genichiro Ishii et al. · 2018 · Cancer Research
48. Therapy-induced DNA methylation inactivates MCT1 and renders tumor cells vulnerable to MCT4 inhibition
    Catherine Vander Linden, Cyril Corbet, Estelle Bastien, Ruben Martherus, Céline Guilbaud, Laurenne Petit, Loris Wauthier, Axelle E. Loriot, Charles De Smet, Olivier Féron · 2021 · Cell Reports
49. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition
    Gabriel T. Bedard, Nord Gilaj, Karina Peregrina, Isabella Brew, Elena Tosti, Karl J. Shaffer, Peter C. Tyler, Winfried Edelmann, Leonard H. Augenlicht, Vern L. Schramm · 2023 · Journal of Biological Chemistry
50. Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities
    Liang Chang, Nancy Yoobin Jung, Adel Atari, Diego J. Rodriguez, Devishi Kesar, Tianyu Song, Matthew G. Rees, Melissa M. Ronan, Ruitong Li, Paloma A. Ruiz et al. · 2023 · Nature Genetics
51. Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5)
    R.L. Palte, Sebastian E. Schneider, Michael D. Altman, Robert P. Hayes, Shuhei Kawamura, Brian M. Lacey, My Sam Mansueto, Michael H. Reutershan, Phieng Siliphaivanh, Christopher Sondey et al. · 2020 · ACS Medicinal Chemistry Letters
52. Long-read sequencing for non-small-cell lung cancer genomes
    Yoshitaka Sakamoto, Liu Xu, Masahide Seki, Toshiyuki Yokoyama, Masahiro Kasahara, Yukie Kashima, Akihiro Ohashi, Yoko Shimada, Noriko Motoi, Katsuya Tsuchihara et al. · 2020 · Genome Research
53. Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions
    Christopher J. Lord, Niall Quinn, Colm J. Ryan · 2020 · eLife
54. Non-Histone Protein Methylation: Biological Significance and Bioengineering Potential
    Roberto Di Blasi, Oleg B. Blyuss, John F. Timms, Daniel Conole, Francesca Ceroni, Harry J. Whitwell · 2021 · ACS Chemical Biology
55. Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers
    Natalie Y.L. Ngoi, Tin‐Yun Tang, Catia Fava Gaspar, Dean C. Pavlick, Gregory M. Buchold, Emma L. Scholefield, Vamsi Parimi, Richard S.P. Huang, Tyler Janovitz, Natalie A. Danziger et al. · 2024 · The Oncologist
56. Targeting Protein Arginine Methyltransferase 5 in Disease
    André Richters · 2017 · Future Medicinal Chemistry
57. Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads
    Mingzong Li, Zenon D. Konteatis, Nelamangala V. Nagaraja, Yue Chen, Shubao Zhou, Guangning Ma, Stefan Größ, Katya Marjon, Marc L. Hyer, Everton Mandley et al. · 2022 · Journal of Medicinal Chemistry
58. The Structure and Function of the PRMT5:MEP50 Complex
    Stephen Antonysamy · 2017 · Sub-cellular biochemistry/Subcellular biochemistry
59. Brain Region-Specific Gene Signatures Revealed by Distinct Astrocyte Subpopulations Unveil Links to Glioma and Neurodegenerative Diseases
    Raquel Cuevas‐Díaz Durán, Chih-Yen Wang, Hui Zheng, Benjamin Deneen, Jia Qian Wu · 2019 · eNeuro
60. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability
    Raunak Shrestha, Marta Llauradó, Amy Dawson, Joshua Hoenisch, Stanislav V. Volik, Yen‐Yi Lin, Shawn A. Anderson, Hannah H. Kim, Anne M. Haegert, Shane Colborne et al. · 2021 · Cancer Research
61. The Influence of Arginine Methylation in Immunity and Inflammation
    Nivine Srour, Sarah Khan, Stéphane Richard · 2022 · Journal of Inflammation Research
62. Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer
    Luying Cui, Ruiqi Liu, Shuling Han, Chunhui Zhang, Bojun Wang, Yuli Ruan, Xuefan Yu, Yien Li, Yuanfei Yao, Xin Guan et al. · 2024 · Cancer Research
63. Antipurinergic therapy for autism—An in-depth review
    Robert K. Naviaux · 2017 · Mitochondrion
64. SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth
    Hironari Tamiya, Hyungsoo Kim, Oleksiy Klymenko, Heejung Kim, Yongmei Feng, Tongwu Zhang, Ji Yun Han, Ayako Murao, Scott J. Snipas, Lucia B. Jilaveanu et al. · 2017 · Journal of Clinical Investigation
65. Targeting allosteric regulation of cancer metabolism
    Daniel M. Kremer, Costas Andreas Lyssiotis · 2022 · Nature Chemical Biology
66. Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion
    Kevin M. Cottrell, Kimberly J. Briggs, Alice Tsai, Matthew R. Tonini, Douglas A. Whittington, Shanzhong Gong, Colin Liang, Patrick R. McCarren, Minjie Zhang, Wenhai Zhang et al. · 2025 · Journal of Medicinal Chemistry
67. The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer
    Ryan V. Quiroz, Michael H. Reutershan, Sebastian E. Schneider, David L. Sloman, Brian M. Lacey, Brooke M. Swalm, Charles See Yeung, Craig R. Gibeau, Daniel S. Spellman, Danica A. Rankic et al. · 2021 · Journal of Medicinal Chemistry
68. Arginine methyltransferase PRMT5 methylates and destabilizes Mxi1 to confer radioresistance in non-small cell lung cancer
    Xijie Yang, Zhen Zeng, Xiaohua Jie, Ye Wang, Jun Han, Zhikun Zheng, Jinsong Li, Hongli Liu, Xiaorong Dong, Gang Wu et al. · 2022 · Cancer Letters
69. Methylthioadenosine phosphorylase deficiency in tumors: A compelling therapeutic target
    Na Fan, Yi Zhang, Suyun Zou · 2023 · Frontiers in Cell and Developmental Biology
70. FXR1 regulates transcription and is required for growth of human cancer cells with TP53/FXR2 homozygous deletion
    Yichao Fan, Jiao Yue, Mengtao Xiao, Han Han‐Zhang, Yao Vickie Wang, Chun Ma, Zhilin Deng, Yingxiang Li, Yanyan Yu, Xinghao Wang et al. · 2017 · eLife
71. Aneuploid CTC and CEC
    Peter Ping Lin · 2018 · Diagnostics
72. Preclinical Models of Malignant Mesothelioma
    Joseph R. Testa, Anton J. M. Berns · 2020 · Frontiers in Oncology
73. MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization
    Landon John Hansen, Rui Yang, Kristen Roso, Wenzhe Wang, Lee Chen, Qing Yang, Christopher J. Pirozzi, Yiping He · 2022 · Scientific Reports
74. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations
    Yuxuan Che, Yang Liu, Yixin Yao, Holly Ann Hill, Yijing Li, Qingsong Cai, Fangfang Yan, Preetesh Jain, Wei Wang, Lixin Rui et al. · 2023 · Blood Cancer Journal
75. The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality
    Chandler Bray, Cristina Domingo Balcells, Iain A. McNeish, Hector C. Keun · 2023 · Frontiers in Oncology
76. Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas
    Omar Alhalabi, Jonathan Thouvenin, Sylvie Négrier, Yann Alexandre Vano, Luca Campedel, Elshad Hasanov, Ziad Bakouny, Andrew Warren Hahn, Mehmet Asım Bilen, Pavlos Msaouel et al. · 2023 · The Oncologist
77. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma
    Michael T. Barrett, Ray Deiotte, Elizabeth Lenkiewicz, Smriti Malasi, Tara Holley, Lisa Evers, Richard G. Posner, Timothy Jones, Haiyong Han, Mark Sausen et al. · 2017 · British Journal of Cancer
78. Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context
    Junfeng Bi, Sihan Wu, Wenjing Zhang, Paul S. Mischel · 2018 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
79. BRAF V600E mutation and 9p21: CDKN2A/B and MTAP co-deletions - Markers in the clinical stratification of pediatric gliomas
    Laura Frazão, Maria do Carmo Martins, Vasco Moura Nunes, José Pimentel, Cláudia C. Faria, José Miguéns, Amets Sagarribay, Mário Matos, Duarte Salgado, Sofia Nunes et al. · 2018 · BMC Cancer
80. Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities
    Sakti Chakrabarti, Mandana Kamgar, Amit Mahipal · 2022 · Cancers
81. Small molecule targeting of chromatin writers in cancer
    Andrew R. Conery, Jennifer L. Rocnik, Patrick Trojer · 2021 · Nature Chemical Biology
82. Genome-guided discovery of cancer therapeutic targets
    Prathyusha Konda, Simon Garinet, Eliezer M. Van Allen, Srinivas Raghavan Viswanathan · 2023 · Cell Reports
83. Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data
    Hiroaki Ikushima, Kousuke Watanabe, Aya Shinozaki‐Ushiku, Katsutoshi Oda, Hidenori Kage · 2025 · ESMO Open
84. Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
    Yunhua Liu, Hanchen Xu, Kevin Van der Jeught, Yujing Li, Sheng Liu, Lu Zhang, Yuanzhang Fang, Xinna Zhang, Milan Radovich, Bryan Paul Schneider et al. · 2018 · Journal of Clinical Investigation · Retracted
85. The Comprehensive Roles of ATRANORIN, A Secondary Metabolite from the Antarctic Lichen Stereocaulon caespitosum, in HCC Tumorigenesis
    Young-Jun Jeon, Sanghee Kim, Ji Hee Kim, Ui Joung Youn, Sung‐Suk Suh · 2019 · Molecules
86. Nutrient availability shapes methionine metabolism in p16/ MTAP -deleted cells
    Sydney M. Sanderson, Peter G. Mikhael, Vijyendra Ramesh, Ziwei Dai, Jason W. Locasale · 2019 · Science Advances
87. Selective PRMT5 Inhibitors Suppress Human CD8+ T Cells by Upregulation of p53 and Impairment of the AKT Pathway Similar to the Tumor Metabolite MTA
    Carolin Dorothea Strobl, Stefanie Schaffer, Tabea Haug, Simon Völkl, Katrin Peter, Katrin Singer, Martin Böttcher, Dimitrios Mougiakakos, Andréas Mackensen, Michael Aigner · 2019 · Molecular Cancer Therapeutics
88. Potent and selective PTDSS1 inhibitors induce collateral lethality in cancers with PTDSS2 deletion
    Yoshihama, Yohei, Namiki, Hidenori, Kato, Taiga, Shimazaki, Naomi, Takaishi, Sachiko, Kadoshima-Yamaoka, Kumiko, Yukinaga, Hideo, Maeda, Naoyuki, Shibutani, Tomoko, Fujimoto, Kazunori et al. · 2022 · Cancer Research
89. TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers
    Kimberly J. Briggs, Kevin M. Cottrell, Matthew R. Tonini, Alice Tsai, Minjie Zhang, Douglas A. Whittington, Wenhai Zhang, Steven A. Lombardo, Satoshi Yoda, Erik Wilker et al. · 2025 · Translational Oncology
90. Specific Targeting of MTAP -Deleted Tumors with a Combination of 2′-Fluoroadenine and 5′-Methylthioadenosine
    Baiqing Tang, Hyung‐Ok Lee, Serim S. An, Kathy Qi Cai, Warren D. Kruger · 2018 · Cancer Research
91. Structure-Aided Design, Synthesis, and Biological Evaluation of Potent and Selective Non-Nucleoside Inhibitors Targeting Protein Arginine Methyltransferase 5
    Deqin Rong, Kaixin Zhou, Wei Fang, Hong Jun Yang, Yi Zhang, Qiongyu Shi, Yuting Huang, Jiayi Li, Hui Fen Dong, Lanlan Li et al. · 2022 · Journal of Medicinal Chemistry
92. Simplifying the B Complex: How Vitamins B6 and B9 Modulate One Carbon Metabolism in Cancer and Beyond
    Carolina N. Franco, Laurence J. Seabrook, Steven T. Nguyen, Jack T. Leonard, Lauren Veronica Albrecht · 2022 · Metabolites
93. Multi-omic and functional analysis for classification and treatment of sarcomas with FUS-TFCP2 or EWSR1-TFCP2 fusions
    Julia Schöpf, Sebastian Uhrig, Christoph E. Heilig, Kwang-Seok Lee, Tatjana Walther, Alexander Carazzato, Anna Maria Dobberkau, Dieter Weichenhan, Christoph Plass, Mark Hartmann et al. · 2024 · Nature Communications
94. PRMT5 silencing selectively affects MTAP‐deleted mesothelioma: In vitro evidence of a novel promising approach
    Marcella Barbarino, Daniele Cesari, Maria Bottaro, Luca Luzzi, Asadoor Amirkhani Namagerdi, Franca Maria Bertolino, Cristiana Bellan, Fabrizio Proietti, Pasquale Somma, Mariacarolina Micheli et al. · 2020 · Journal of Cellular and Molecular Medicine
95. Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
    Felix Orben, Katharina Lankes, Christian Schneeweis, Zonera Hassan, Hannah Jakubowsky, Lukas Krauß, Fabio Boniolo, Carolin Schneider, Arlett Schäfer, Janine Murr et al. · 2022 · JCI Insight
96. Cancer Dependencies: PRMT5 and MAT2A in MTAP/p16-Deleted Cancers
    Katya Marjon, Peter Kalev, Kevin M. Marks · 2020 · Annual Review of Cancer Biology
97. MTAP as an emerging biomarker in thoracic malignancies
    Magdalena M. Brune, Spasenija Savic Prince, Tatjana Vlajnic, Obinna Chijioke, Luca Roma, David König, Lukas Bubendorf · 2024 · Lung Cancer
98. Genomics-guided pre-clinical development of cancer therapies
    Hayley E. Francies, Ultan McDermott, Mathew J. Garnett · 2020 · Nature Cancer
99. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma
    Jasmin Elurbide, Leticia Colyn, Maria Ujue Latasa, Iker Uriarte, Stefano Mariani, Amaya López-Pascual, Emiliana Valbuena-Goiricelaya, Borja Castelló-Uribe, Robert Arnes‐Benito, Elena Adán-Villaescusa et al. · 2024 · Gut
100. Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma
     Peng Sen Wu, Jia-Li Liu, Shi-Mei Pei, Chang-Peng Wu, Kai Ge Yang, Shu-Peng Wang, Song Wu · 2018 · BMC Cancer